Description: Hertraz is a medication that contains the active ingredient trastuzumab. Trastuzumab is a monoclonal antibody designed to target and inhibit the activity of the HER2/neu (human epidermal growth factor receptor 2) protein, which is overexpressed in certain types of cancer cells, particularly HER2-positive breast cancer.

Indications: Hertraz is commonly prescribed for the treatment of HER2-positive breast cancer, a subtype of breast cancer where the cancer cells have an increased number of HER2 receptors. This medication is used in both early-stage and advanced-stage breast cancer, either as part of the neoadjuvant or adjuvant treatment regimen or for metastatic disease.

Mechanism of Action: Trastuzumab works by binding to the HER2 receptors on the surface of cancer cells. By doing so, it interferes with the signaling pathways associated with HER2, leading to a reduction in the growth and division of cancer cells. This targeted approach helps to inhibit the progression of HER2-positive breast cancer.

Administration: Hertraz is typically administered through intravenous (IV) infusion. The dosage and schedule are determined by the treating oncologist based on factors such as the stage of cancer, overall health, and the patient’s response to the treatment.

Side Effects: Common side effects of trastuzumab may include nausea, diarrhea, fatigue, headache, and infusion-related reactions. Some patients may experience more serious side effects, and it’s important to promptly report any unusual symptoms to the healthcare provider.

Precautions: Patients receiving Hertraz are often closely monitored for cardiac function, as trastuzumab may have an impact on the heart. Regular cardiac assessments, including echocardiograms, may be performed during treatment. It is not recommended for use during pregnancy, and appropriate contraception is advised during and after treatment.

Hertraz is a crucial component of targeted therapy for HER2-positive breast cancer, and its use is determined based on the individual characteristics of the cancer and the patient. As with any medication, specific details may vary, and patients should rely on the guidance of their healthcare provider for personalized information and advice.